Disputas – cand.med Øyvind Holsbø Hald (strømmes)

Avhandlingen er tilgjengelig her.

The doctoral thesis.

The auditorium will be closed to the public because of the corona outbreak. The defense will be streamed. A recording of the disputation will be available for one week.

Prøveforelesning starter kl 10:15. 

Prøveforelesningen har følgende tittel: "Development of the sympathetic nervous system in relation to neuroblastoma"

Prøveforelesningen strømmes her.

The trial lecture will be streamed here. 

Disputasen starter kl 12:00 og blir strømmet fra aud. Cortex. 

Disputasen vil i stedet bli strømmet her.

The defense will be streamed here.

De som ønsker å opponere ex auditorio kan sende e-post til leder av disputasen, Natalia Ermolina.
Opponents ex auditorio should sign up to leader of defense by e-mail til Natalia Ermolina.

Populærvitenskapelig sammendrag av avhandlingen:

Neuroblastoma is a cancer of childhood. 50% of high-risk patients survive the disease, and most of those who are cured, will experience treatment related late effects. Better therapy is needed. In this thesis, we have investigated molecular aspects of high-risk neuroblastoma using patient-derived cell lines, different molecular biology techniques, and a mouse model. We have shown that chemicals, which target RNA-molecules responsible for protein production in a cell, are effective in killing neuroblastomas. We also show that treatment with a particular small RNA molecule reduces the ability of neuroblastoma cells to grow and leads to cell death. Finally, we found that neuroblastoma cells release a distinct group of small RNA molecules into their surrounding environment. In conclusion, the discoveries presented in this thesis, can hopefully lead to better future therapies and biomarkers in high-risk neuroblastoma.

Hovedveileder

Professor II Christer Einvik, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitetet

Biveiledere

Professor Baldur Sveinbjørnsson, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Professor Trond Flægstad, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Bedømmelseskomité

Professor Marie Arsenian-Henriksson, Karolinska Institutet, Sverige – 1. opponent

Professor Håkan Axelson, Lund University Cancer Centre, Sverige – 2. opponent

PhD Lorena Arranz, Institutt for medisinsk biologi, UiT Norges arktiske universitet – leder av komitè

Disputasleder: Seniorrådgiver Natalia Ermolina, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet